Pharma Unites to Tackle Data Chaos with New Assay Repository

CAMBRIDGE, Mass. and CAMBRIDGE, England – May 26, 2026 – In a significant move to combat a long-standing data crisis in drug development, informatics leader Zifo and the Pistoia Alliance, backed by pharmaceutical giants, have launched a global platform designed to standardize how crucial research data is recorded and shared. The In Vitro Pharmacology (IVP) Assay Repository, developed with input from AbbVie, Novartis, Merck, and Roche, aims to dismantle the "data silos" that have hampered innovation and contributed to the industry's multi-billion-dollar reproducibility problem.

This initiative provides a centralized, open framework for researchers to register and manage biological assays—the fundamental experiments used to test drug candidates—in a consistent and transparent way, promising to accelerate the path from lab to clinic.

The Battle Against Data Fragmentation

For years, the life sciences industry has been plagued by a paradox: while generating unprecedented volumes of data, its ability to effectively use that data has been severely limited. A significant part of this challenge stems from fragmented in vitro pharmacology data and inconsistent assay documentation. This isn't just an academic issue; it has profound real-world consequences, contributing to what many call a "reproducibility crisis" where preclinical research findings often cannot be replicated, wasting billions of dollars and countless hours of scientific effort annually.

Within a single large pharmaceutical company, let alone across the entire industry, different teams often document the same type of experiment in slightly different ways. This lack of standardization makes it incredibly difficult to compare results, integrate data from different studies, or reuse valuable information generated by partners and contract research organizations (CROs). Scientists spend an inordinate amount of time on "manual data cleanup"—a tedious process of trying to harmonize disparate datasets—instead of focusing on scientific discovery. This inefficiency not only slows down the identification of promising drug candidates but also complicates the already arduous process of submitting data to regulatory bodies like the FDA and EMA for approval.

The new IVP Assay Repository directly confronts this issue. "By enabling a standardized way to register protocols, the Assay Repository facilitates the systematic transmission of in vitro pharmacology data reducing the time spent on manual data cleanup and ensuring that critical safety information is both transparent and easily accessible," said Christian Baber, Chief Portfolio Officer at Pistoia Alliance, in the launch announcement.

A Collaborative Blueprint for Open Science

Perhaps the most remarkable aspect of the IVP Assay Repository is not just the technology itself, but the pre-competitive collaboration that brought it to life. The project is a prime example of a growing trend where fierce competitors in the pharmaceutical industry are choosing to unite to solve shared, foundational problems. The steering committee, featuring representatives from AbbVie, Novartis, Merck, and Roche, underscores the high-level buy-in for a collective solution.

This collaborative spirit is fostered by the Pistoia Alliance, a global non-profit organization founded with the express purpose of lowering barriers to innovation through such partnerships. With a membership that includes 18 of the top 20 global pharmaceutical companies, the Alliance provides the legal and operational framework that allows members to pool resources and expertise on challenges that are too large or complex for any single entity to solve alone, without compromising their individual competitive advantages. Its successful track record includes developing standards for chemical safety data and improving data interoperability in electronic lab notebooks, making it the ideal convener for this initiative.

By creating a shared resource, the participating companies acknowledge that a rising tide of better, more reliable data will lift all boats. The goal is not to share proprietary drug compounds or clinical trial results, but to standardize the fundamental language and structure of early-stage research data, creating a more efficient and robust ecosystem for everyone.

Under the Hood: Zifo’s Technical Architecture

Serving as the development and implementation partner, Zifo brought its deep expertise in scientific informatics to build the repository's underlying platform. The company’s contribution went far beyond simple software development, involving a two-year collaborative effort to design a system that could meet the complex needs of scientists, data managers, and regulators.

The repository's power lies in its structured approach. It employs controlled vocabularies and standardized data fields to ensure that every assay registered on the platform is described consistently. Critically, the system builds upon established public ontologies like the Bioassay Ontology (BAO), a formal classification system for describing biological assays. This integration ensures the repository doesn't reinvent the wheel but rather enhances and operationalizes existing standards, making the data semantically interoperable, or machine-readable.

This technical foundation directly supports the FAIR data principles—ensuring data is Findable, Accessible, Interoperable, and Reusable. For a researcher, this means they can easily search the repository for a specific type of assay, understand its design and parameters, and confidently reuse or compare its results.

"Over the past two years, Zifo has been proud to collaborate with the Pistoia Alliance and its member community to help design and build this standardized biological assay registration platform," said Aishwarya Balajee, Head of Scientific Data and Digital at Zifo. "By enabling interoperable assay registration within a shared, open framework, the IVP Assay Repository helps the industry consistently describe, discover, and reuse assays across organizations. We look forward to seeing the broader scientific community leverage this platform to strengthen collaboration, improve reproducibility, and accelerate innovation."

Accelerating Discovery and Navigating Adoption

The ultimate goal of the IVP Assay Repository is to accelerate the delivery of new medicines. By providing a "shared foundation," as Baber describes it, the platform is expected to enhance data exchange between pharma companies and their CRO partners, improve the consistency of data submitted for Investigational New Drug (IND) applications, and ultimately foster greater trust and reproducibility in preclinical science.

The initiative aligns perfectly with the direction of regulatory agencies, which are increasingly advocating for standardized, high-quality digital data to make their review processes more efficient and effective. However, the path to widespread adoption is not without challenges. The industry must overcome cultural resistance to change, as organizations will need to adapt long-standing internal workflows. Integrating the new platform with a complex web of existing legacy IT systems will also require significant effort and investment.

Recognizing these hurdles, the Pistoia Alliance and Zifo are launching version 1.0 with an open invitation for feedback from the broader life sciences community. This iterative approach is designed to ensure the platform evolves to meet the real-world needs of researchers and data scientists. As governance models are refined and more organizations begin to contribute, the repository's value is expected to grow exponentially, creating a network effect that could finally help the industry escape its cycle of fragmented data and unlock a new era of collaborative, data-driven discovery.